David M. O’Malley

Jan 8, 2025 | nature.com | Jyoti S. Mayadev |Dmitriy Zamarin |Heather A. Lankes |Barbara L. Banbury |Cara Mathews |David M. O’Malley | +1 more

AbstractCombined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.

Sep 6, 2023 | oncpracticemanagement.com | Pashtoon M. Kasi |David M. O’Malley

Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he describes the outcomes and study design of clinical trials evaluating targeted therapeutic options for patients with mCRC.

Sep 6, 2023 | oncpracticemanagement.com | Pashtoon M. Kasi |David M. O’Malley

Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, explores potential best practice approaches to biomarker testing in mCRC.

Sep 6, 2023 | oncpracticemanagement.com | Pashtoon M. Kasi |David M. O’Malley

Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he discusses the trends and outcomes of older patients compared to younger patients who received 1L chemotherapy for mCRC.

Sep 6, 2023 | oncpracticemanagement.com | Pashtoon M. Kasi |David M. O’Malley

Please join Pashtoon Kasi, MD, MS, from Weill Cornell Medicine and Englander Institute of Precision Medicine, as he discusses pivotal presentations from ASCO 2023 focused on metastatic colorectal cancer (mCRC).